SLC7A11 and neoplasm: (31) showed that LUAD tumors with concurrent mutations in serine/threonine kinase 11 (STK11) and KEAP1 were more resistant to ferroptosis since the activity of NRF2 pathway and targets involved in ferroptosis such as SLC7A11 and GPX4 were increased, leading to worse overall survival and enhanced tumor proliferation both in vivo and in vitro (Figure 2).